Peptides for Depression: The Evidence

Depression is a clinical diagnosis, not a mood you can supplement away. It involves changes across serotonergic, dopaminergic, and stress-hormone systems, and it carries real risk when untreated. A peptide cannot diagnose you, monitor your response, or catch a worsening episode.

Standard treatments have decades of large-scale trial data behind them. SSRIs, SNRIs, psychotherapy, and in some cases ketamine or ECT are first-line for a reason. The peptides covered here have nothing close to that evidence base.

Think of the research here like a weather forecast built from three readings instead of a satellite network. The direction might be right, but the confidence is low and the error bars are wide. The literal point: treat every claim below as preliminary until human trials confirm it.

If you take any of this seriously, the first step is a conversation with a licensed clinician, not a vial. For the broader safety framework around research peptides, read our peptide safety guide before anything else.

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its strongest data is in anxiety, but the same trials noted mood-relevant "anti-asthenic" effects, meaning reduced fatigue and low motivation that often travel with depression.

In a 62-patient trial in generalized anxiety disorder, Selank matched a benzodiazepine for anxiolytic effect while also showing anti-asthenic and mild psychostimulant properties, with no sedation (Zozulya et al., Bull Exp Biol Med, 2008). Patients felt less drained, which matters for the anergic side of low mood.

A molecular study found Selank alters expression of genes governing GABAergic neurotransmission and serotonin turnover (Volkova et al., PMC4757669, 2016). That serotonin link is the thread connecting it to mood, though no trial has tested Selank as a standalone antidepressant.

The overlap between anxiety and depression is large, which is why our companion guide on peptides for anxiety covers Selank in more depth. Selank is not approved as an antidepressant anywhere, and US availability is as a research compound only.

Semax is a synthetic analogue of ACTH(4-10), approved in Russia since the 1990s for cognitive and neurological conditions. Its relevance to depression runs through BDNF, the growth factor that low mood and chronic stress tend to deplete.

Semax rapidly elevates BDNF and TrkB receptor expression in the hippocampus, the region most tied to emotional regulation (Dolotov et al., J Neurochem, 2006). Restoring BDNF is one of the proposed mechanisms by which SSRIs eventually work, which makes the signal interesting rather than conclusive.

Animal stress models show Semax buffering against stress-induced behavioral changes, and human cognitive studies report improved mental clarity and emotional stability (Kaplan et al., Neurosci Behav Physiol, 2008). The cognitive angle matters because brain fog and slowed thinking are core depression symptoms, covered further in our cognitive function guide.

One caveat: a 1996 report noted a possible anxiogenic component at higher doses, so Semax suits low mood paired with fatigue and fog better than agitated or anxious presentations. It is not an FDA-approved antidepressant.

BPC-157 is a 15-amino-acid peptide derived from a protein in gastric juice. Most people use it for tissue repair, but its antidepressant-like effects in rodents are what put it on this list. The mechanism is the gut-brain axis.

In Porsolt's forced swim test and chronic unpredictable stress models, BPC-157 produced antidepressant-like effects comparable to standard agents like imipramine (Sikiric et al., Curr Neuropharmacol, 2016). Within roughly 40 minutes of dosing it shifts serotonin synthesis regionally, increasing it in some areas while lowering it in others (Tohyama et al., 2004).

Here is the practical link: a large share of people with depression also have gut symptoms, and the gut produces most of the body's serotonin. BPC-157 heals the gut lining while modulating brain neurotransmitters, a dual action no SSRI offers.

The evidence ceiling is firm, though. These are animal studies with no human depression trials. BPC-157 was placed in FDA Category 2 in 2023 and cannot be legally compounded in the US. Anyone reconstituting research material should still use a peptide reconstitution calculator and follow proper injection technique.

DSIP, Delta Sleep-Inducing Peptide, was first isolated in 1977. It does not target mood directly. It targets sleep and stress hormones, and those drive a large share of depressive symptoms.

Poor sleep is both a symptom and a driver of depression. DSIP promotes natural delta-wave sleep and, in a 1984 human study, subjects reported better relaxation and improved tolerance against psychic stress (Schneider-Helmert, Eur Neurol, 1985). Restoring deep sleep can lift the daytime heaviness that sleep deprivation amplifies.

DSIP also dampens ACTH and cortisol surges. Chronic cortisol elevation damages the hippocampus and is a consistent finding in depression, so normalizing the HPA axis addresses one neuroendocrine root of low mood (Graf & Kastin, Neurosci Biobehav Rev, 1986).

For people whose low mood is tangled with insomnia and 3 a.m. rumination, the sleep angle may matter more than any direct mood effect. Our peptides for sleep guide covers DSIP protocols. It is not approved for medical use in any country.

GLP-1 receptor agonists like semaglutide are not mood drugs, and the data on their mental health effects is genuinely mixed. They earn a place here because metabolic health and depression are biologically entangled.

Obesity, insulin resistance, and chronic low-grade inflammation all correlate with higher depression rates, and GLP-1 agonists act on all three. Some research suggests GLP-1 signaling reduces neuroinflammation, a pathway implicated in depression (Kim et al., Front Neurosci, 2020).

The human picture is unsettled. Large pharmacovigilance reviews have found no clear increase in suicidality with semaglutide, and some cohort data hint at lower depression incidence, but causation is not established (McIntyre et al., 2024).

The honest read: any mood benefit is likely indirect, flowing through weight loss, better metabolic markers, and reduced inflammation rather than a direct antidepressant action. For the energy and motivation side of low mood, our peptides for energy guide covers related compounds. GLP-1 agonists are FDA-approved for diabetes and weight management, not depression.

Three honest limits define this entire field. The evidence is preliminary, the regulatory status is research-only for most of these compounds, and depression itself is too serious to self-manage.

Consider the scale of the evidence gap. SSRIs are backed by hundreds of randomized trials enrolling tens of thousands of patients. Selank's strongest human dataset is a single 62-person trial, and BPC-157's antidepressant signal exists only in rodents. That is a difference of three or four orders of magnitude in human evidence.

The practical consequence: stopping a prescribed antidepressant to try a peptide can trigger discontinuation symptoms and relapse within weeks, with no proven replacement catching you. Never taper or stop prescribed medication without your physician's guidance.

If you are exploring peptides, the safest framing is as a possible adjunct to discuss with a clinician, never a substitute for medication or therapy. Review general dosing context in our peptide dosage chart, and remember that quality varies wildly between research suppliers.

Stopping antidepressants to try a peptide. Discontinuing an SSRI cold can cause withdrawal symptoms, return of depression, and rising suicide risk within one to two weeks. The fix: never stop prescribed medication without your prescriber. Peptides like Selank have no data showing they can hold the line an antidepressant was holding.

Treating animal data as proof. BPC-157's antidepressant-like results come entirely from rodent models. Roughly 90% of compounds that work in animal studies fail in human trials. The fix: weigh evidence by tier, and read the honest limits in our peptide safety guide.

Ignoring a crisis while researching. No peptide protocol matters during an acute crisis. If you have thoughts of self-harm, contact 988 immediately. The fix: treat crisis as a medical emergency, separate from any research interest.

Skipping the clinician. Drug interactions between serotonergic peptides and prescribed antidepressants carry a theoretical serotonin syndrome risk. The fix: tell your prescriber about anything you are considering before starting, and verify dosing with a reconstitution calculator only after professional sign-off.